Business · 22/10/20261 min read
Rznomics has been awarded the Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission.
Summary
SEONGNAM, South Korea, 22 October 2026 — Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted...